Proven effective at reducing c-Met phosphorylation, cell migration, and tumor proliferation in preclinical glioblastoma models, onartuzumab has been evaluated in phaseI/II trials in solid tumors and in combination with the EGFR inhibitor erlotinib in NSCLC. Here, EGFR is linked to neoplasm.